Skip to main content
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRKR ISIN · US57055L1070 US Manufacturing
Open in API
Filings indexed 899 across all filing types
Latest filing 2008-07-25 Regulatory Filings
Country US United States of America
Listing US MRKR

About Marker Therapeutics, Inc.

https://markertherapeutics.com/

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology is its Multi-Antigen Recognizing (MAR) T cell platform, which utilizes natural, non-genetically modified T cells to recognize and kill heterogeneous tumors. This approach is designed to provide durable anti-tumor responses with a favorable safety profile. Its lead product candidate, MT-601, recognizes six tumor-specific antigens and is being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. The technology was originally developed at Baylor College of Medicine.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2008
Regulatory Filings
2008-07-25 English
PRIMARY DOCUMENT
Director's Dealing
2008-06-25 English
TAPIMMUNE, INC.
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 2, 2008. It reports the repayment of a loan evidenced by secured promissory notes. The content is a brief update on a financing event, specifically the repayment of debt, and does not contain financial statements or detailed financial analysis. The document length is 2740 characters, which is relatively short and consistent with a current report rather than a full financial report. The nature of the content aligns with updates on capital structure or financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2008-06-05 English
TAPIMMUNE, INC.
Interim / Quarterly Report Q1 2008
2008-05-20 English
TAPIMMUNE, INC.
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the company, TapImmune Inc, was unable to file its Form 10-Q (quarterly report) for the period ended March 31, 2008, within the prescribed time due to inability to obtain necessary business information and auditor review. The form requests an extension to file the report within the allowed grace period. This document does not contain the actual financial data or the report itself but is a regulatory notification about the delay in filing the interim quarterly report. According to the classification rules, such a notification is a Regulatory Filing (RNS) and not the actual Interim/Quarterly Report (IR).
2008-05-15 English
TAPIMMUNE, INC.
Annual Report Classification · 100% confidence The document is titled 'FORM 10-KSB' and is described as an 'ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934' for the fiscal year ended December 31, 2007. It contains detailed company information, including business description, market information, management discussion, and financial statements. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of SEC form identifiers and the detailed content confirms this is the official annual report filing. Therefore, the document is classified as an Annual Report (10-K).
2008-04-14 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.